Infection with hepatitis C is one of the main causes of liver disease, yet there are no broadly effective treatments. Discovery of a potent inhibitor of this virus shows that researchers must think outside the box.
This is a preview of subscription content, log in via an institution to check access.
References
Gao, M. et al. Nature 465, 96–100 (2010).
Ge, D. et al. Nature 461, 399–401 (2009).
Suppiah, V. et al. Nature Genet. 41, 1100–1104 (2009).
Tanaka, Y. et al. Nature Genet. 41, 1105–1109 (2009).
De Francesco, R. & Migliaccio, G. Nature 436, 953–960 (2005).
Kwong, A. D., McNair, L., Jacobson, I. & George, S. Curr. Opin. Pharmacol. 8, 522–531 (2008).
Lemm, J. A. et al. J. Virol. 84, 482–491 (2010).
Tellinghuisen, T. L., Foss, K. L. & Treadaway, J. PLoS Pathog. 4, e1000032 (2008).
Appel, N. et al. PLoS Pathog. 4, e1000035 (2008).
Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Nature 435, 374–379 (2005).
Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. N. J. Virol. 83, 4395–4403 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murray, C., Rice, C. An unsuspected drug target. Nature 465, 43–44 (2010). https://doi.org/10.1038/465042a
Published:
Issue Date:
DOI: https://doi.org/10.1038/465042a
- Springer Nature Limited
This article is cited by
-
TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein
Scientific Reports (2016)
-
Hepatitis C: move over interferon
Nature Biotechnology (2011)